The Relative Strength (RS) Rating for AdaptHealth jumped into a higher percentile Tuesday, as it got a lift from 63 to 77.
IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 as they begin their biggest climbs. See if AdaptHealth can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
AdaptHealth is building a consolidation with an 11.90 entry. See if it can clear the breakout price in heavy trading.
AdaptHealth posted 0% EPS growth in its most recent report, while sales growth came in at 0%.
AdaptHealth earns the No. 8 rank among its peers in the Medical-Outpatient/Home Care industry group. BrightSpring Hlth Svcs, Encompass Health and Addus HomeCare are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
